TEVA PHARMACEUTICAL INDUSTRIES LTD【TEVA】Cash flow
Market cap
$36.7B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 80 | 91 | 82 | 64 | 95 | 117 | 124 | 133 | 155 | 119 | 129 | 119 | 124 | 121 | 123 |
| Cash from operations | 4,136 | 4,134 | 4,572 | 3,237 | 5,127 | 5,542 | 5,225 | 3,507 | 2,446 | 748 | 1,216 | 798 | 1,590 | 1,368 | 1,247 |
| Capital expenditures | -710 | -1,053 | -1,104 | -1,031 | -929 | -772 | -901 | -874 | -651 | -525 | -578 | -562 | -548 | -526 | -498 |
| Cash from investing | -5,455 | -7,601 | -1,134 | -1,147 | -1,450 | -5,565 | -35,740 | 2,164 | 1,866 | 1,355 | 863 | 1,523 | 656 | 968 | 792 |
| Repurchases of common stock | 99 | 899 | 1,161 | 497 | 500 | 439 | - | - | - | - | - | - | - | - | - |
| Repayments of term debt | 1,972 | 751 | 2,213 | 3,133 | 839 | 2,521 | 999 | 3,300 | 7,446 | 3,944 | 1,871 | 6,649 | 1,369 | 4,152 | 1,641 |
| Cash from financing | 573 | 3,336 | -1,678 | -3,883 | -2,375 | 4,805 | 25,217 | -5,750 | -3,351 | -1,926 | -1,885 | -2,172 | -1,487 | -1,913 | -1,791 |
| Free cash flow | |||||||||||||||
| FCF margin (%) |